|
|
- 2018
新辅助化疗对不同分子亚型乳腺癌免疫标记表达的影响
|
Abstract:
摘要 目的: 分析不同分子亚型乳腺癌患者新辅助化疗后临床病理缓解及免疫标记表达变化情况,探讨这些指标变化的临床意义及与新辅助化疗疗效的相关性.方法:收集221例接受蒽环类联合紫杉类药物新辅助化疗并成功施行手术的乳腺癌患者,通过S-P免疫组化检测对比新辅助化疗前后雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(HER-2)及细胞增殖抗原(Ki-67)的表达情况.结果:在221例乳腺癌患者中,Luminal A型的临床有效缓解率(CR+PR)低于其他3组病例(P=0.037),三阴性(17.54%)及Her-2过表达型(25.64%)的病理完全缓解率(pCR)明显高于Luminal A型(7.14%)及Luminal B型(7.23%).新辅助化疗后不同分子亚型乳腺癌患者的ki-67的下降是有差异的(P=0.04)且Ki-67的变化与新辅助化疗的疗效相关联(CR+PR)(P=0.000),而ER、PR、Her-2受体状态的变化无统计学差异(P＞0.05).结论:新辅助化疗可以明显降低Ki-67的表达且与分子分型密切相关,但对ER、PR及Her-2表达的影响甚微.Ki-67可作为新辅助化疗疗效的预测指标.
| [1] | XIAN Z, QUINONES A K, TOZBIKIAN G, et al. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?[J]. Human Pathology, 2017, 62(5): 215-221. DOI:10.1016/j.humpath.2016.12.019 |
| [2] | JIN G, HAN Y, LIU C, et al. Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer[J]. Int J Clin Exp Pathol,2015,8(1):914-921. |
| [3] | PARINVANITIKUL N, LEI X, CHAVEZ-MACGREGOR M, et al. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and of survival outcomes[J]. Clin Breast Cancer, 2015,15(2):153-160. |
| [4] | ENOMOTO Y, MORIMOTO T, NISHIMUKAI A, et al. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers[J]. Int J Clin Oncol, 2016, 21(2): 254-261. |
| [5] | 杨文涛, 步宏. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志, 2015,44(4):237-239. |
| [6] | YANG W T, BU H. Immunohistochemical detection guidelines of breast cancer oestrogen and progesterone receptor[J]. Chinese Journal of Pathology, 2015,44(4): 237-239. |
| [7] | <BREAST CANCER HER2 TEST GUIDELINES>WRITING GROUP. Breast cancer her2 test guidelines(2014)[J]. Chinese Journal of Pathology, 2014, 43(4):262-267. |
| [8] | 郭莉,李迅,杨顺娥,等.TE及NE方案在乳腺癌新辅助化疗中疗效及毒副反应的比较[J]. 广东医学, 2014, 35(7): 1039-1042. |
| [9] | CHENG Y J, YE J M, XU L, et al. Factors related with pathological complete response of neoadjuvant chemotherapy in primary breast cancer[J]. Zhonghua Wai Ke Za Zhi, 2013, 51(4): 339-343. |
| [10] | MIGLIETT L,MORABITO F,PROVINCIALI N,et al.A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients[J]. Eur J Surg Oncol, 2013, 39(10): 1046-1052. doi:10.1016/j.ejso.2013.06.024. |
| [11] | 李小雷. 乳腺癌新辅助化疗后ER、PR、HeR-2、Ki67的变化及相关影响因素分析[D]. 浙江大学, 2015,36(4):568-580. |
| [12] | CHEN S, CHEN C M, YU K D, et al. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer[J]. Ann Surg Oncol, 2012, 19(9): 3002-3011. doi:10.1245/s10434-012-2318-2. |
| [13] | VAN DALUM G, VAN DER StAM G J, TIBBE A G, et al. Circulating tumor cells before and during follow-up after breast cancer surgery[J]. Int J Oncol, 2015, 46(1): 407-413. doi:10.3892/ijo.2014.2694. |
| [14] | LIU Q, ZUO W S, WANG X Z, et al. Correlation analysis of hormone receptors and the expressions of HER-2 and Ki-67 in breast cancer[J]. Eur J Gynaecol Oncol, 2015, 36(1): 78-83. |
| [15] | KONTZOGLOU K, PALLA V, KARAOLANIS G, et al. Correlation between Ki67 and Breast Cancer Prognosis[J]. Oncology, 2013, 84(4):219-225. |
| [16] | 《乳腺癌HER检测指南》编写组. 乳腺癌HER2检测指南(2014版)[J]. 中华病理学杂志, 2014, 43(4):262-267. |
| [17] | YI M. China anticancer association guidelines for the diagnosis and treatment of breast cancer(2015)[J]. China Oncology, 2015,25(9): 692-754. |
| [18] | GUO L, LI X, YANG S E, et al. TE and NE solutions of neoadjuvant chemotherapy for breast cancer in the comparison of curative effect and adverse reaction[J].Guangdong Medical Journal, 2014,35(7):1039-1042. |
| [19] | 陈崇,周桃玉,温旺荣.乳腺癌组织中 Ki-67 表达及其临床意义的 Meta分析[J].肿瘤学杂志,2014,20(4):270-275. |
| [20] | NIIKURA N, TOMOTAKI A, MIYATA H, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21755 patients from the, Japanese breast cancer registry[J]. Ann Oncol,2016, 27(3):480-487. |
| [21] | 贾巍, 张红真, 王文娟,等. 新辅助化疗前后乳腺癌免疫组化表达变化的研究分析[J]. 浙江医学, 2016, 38(14):1181-1183. |
| [22] | JIA W, ZHANG H Z, WANG W J, et al.Changes of biological indexes in patients with breast cancer after neoadjuvant chemotherapy[J]. Zhejiang Medical, 2016, 38(14):1181-1183. |
| [23] | QIN Q, GAO F, JIANG W, et al. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer[J]. Chin Med J(Engl), 2014, 127(18): 3272-3277. |
| [24] | 佚名. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J]. 中国癌症杂志, 2015,25(9):692-754. |
| [25] | GE W K, YANG B, ZUO W S, et al. Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients[J]. Thorac Cancer, 2015, 6(1): 64-69. doi:10.1111/1759-7714.12133. |
| [26] | COCKBURN A, YAN J, RAHARDJA D, et al. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer[J]. Hum Pathol, 2014, 45(2): 249-258. |
| [27] | CHEN C, ZHOU T Y, WEN W R. Expression of Ki-67 in breast cancer and its clinical significance: a meta-analysis[J]. Journal of Oncology, 2014,20(4):270-275. |
| [28] | 刘英,黄建军. 乳腺癌新辅助化疗前后 ER、 PR、 Her2、 EGFR、 CK5/6 的表达及预测化疗效果的意义[J]. 贵阳医学院学报, 2014,39(5):70-75. |
| [29] | LIU Y, HUANG J J. Expression of ER, PR, HER-2, EGFR and CK5/6 in breast cancer tissue before and after neoadjuvant chemotherapy and its significance in predicting chemotherapeutic effects[J]. Journal of Guiyang Medical College, 2014,39(5):70-75. |
| [30] | LI X L.Discordances in ER, PR, HER-2 and ki-67 after neo-adjuvant chemotherapy in breast cancer and analysis of the correlated influence factor[D].Zhejiang University, 2015,36(4):568-580. |
| [31] | RAKOVITCH E, NOFECH-MOZES S, HANNA W, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinomain situ[J]. British Journal of Cancer, 2012, 106(6):1160-1165. |
| [32] | LI M, ZHAO L, SHEN D, et al. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma[J].Chin Med J, 2014, 127(8): 1459-1463. |
| [33] | MATSUBARA N, MUKAI H, FUJII S, et al. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer[J]. Breast Cancer Research & Treatment, 2013, 137(1):203-212. |
